Bio-Rad Extends Anti-Idiotypic Antibody and SpyCatcher Reagent Ranges for Bioanalysis and Antibody Drug Development
Additions to Company’s Range of Bioanalytical Antibodies and Reagents Enhances Bioanalysis and Antibody-Related Research
HERCULES, Calif. — June 17, 2025 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today extended its range of recombinant monoclonal anti-idiotypic antibodies with the introduction of antibodies specific to pertuzumab (Perjeta), guselkumab (Tremfya), canakinumab (Ilaris), belimumab (Benlysta), and the bispecific drug emicizumab (Hemlibra). The Company has also extended its range of SpyCatcher reagents to include Human IgM-FcSpyCatcher.
Bio-Rad’s comprehensive range of anti-biotherapeutic antibodies enables the development of robust and reliable bioanalytical assays against biologic drugs and is suitable for use in pharmacokinetic (PK) and anti-drug-antibody (ADA) assays for pertuzumab, guselkumab, canakinumab, belimumab, and emicizumab, facilitating therapeutic drug monitoring for innovator and biosimilar products.
The new Human IgM-FcSpyCatcher adds to Bio-Rad’s SpyCatcher collection — it is a unique reagent that allows researchers to rapidly switch antibody formats at the protein level, enabling spontaneous formation of pentameric and hexameric IgMs. Compatible with Bio-Rad’s recombinant HuCAL antibodies, the new SpyCatcher reagent has been successfully tested in ELISA, western blotting, and precipitation assays.
“Bio-Rad’s leading portfolio of monoclonal anti-idiotypic antibodies is extensive; with 45 different specificities and more than 250 antibodies, we are providing greater flexibility for the development of highly selective and highly sensitive bioanalytical assays,” said Hilary Mavor, Marketing Director, Life Science Group, Bio-Rad. “With the addition of the new SpyCatcher protein, we are continuing to deliver new and innovative bioanalysis tools for both our custom and catalog antibody customers, driving advances in antibody drug discovery.”
The new antibodies and reagents are approved for in vitro research, with the anti-idiotypic antibodies also approved for commercial in vitro testing services to support preclinical and clinical drug and biosimilar development, and patient monitoring.
Learn more about Bio-Rad’s anti-idiotypic antibodies or explore our SpyCatcher reagents.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 7,700 employees and $2.6 billion in revenues in 2024. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.
Forward-Looking Statements
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our products and our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include risks relating to our international operations, global economic and geopolitical conditions, tariffs or other trade barriers, reductions in government funding or capital spending of our customers, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, supply chain risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad's public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Media Contacts:
Bio-Rad Laboratories, Inc.
Katrina Academia, Inbound Marketing Manager
+1 510-356-7909
Zyme Communications
Dr. Maria Spyrou
+44 (0) 7707 049 640